Revelation Biosciences, Inc. (NASDAQ:REVB) Short Interest Up 937.8% in November

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant growth in short interest in November. As of November 15th, there was short interest totalling 428,600 shares, a growth of 937.8% from the October 31st total of 41,300 shares. Based on an average trading volume of 541,700 shares, the short-interest ratio is presently 0.8 days. Approximately 10.0% of the company’s stock are short sold.

Revelation Biosciences Stock Performance

Shares of Revelation Biosciences stock traded up $0.00 on Wednesday, reaching $0.75. The stock had a trading volume of 121,756 shares, compared to its average volume of 853,843. Revelation Biosciences has a fifty-two week low of $0.70 and a fifty-two week high of $25.26. The business’s 50-day moving average price is $0.83 and its two-hundred day moving average price is $1.33. The stock has a market cap of $3.22 million, a P/E ratio of -0.04 and a beta of 0.15.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.